Oxidative stress and its implications for future treatments and management of alzheimer disease

International Journal of Biomedical Science

Volumn 6, Issue 3, 2010, Pages 225-227

  Clark, Timothy A ^g   Lee, Hyun Pil ^a   Rolston, Raj K ^b   Zhu, Xiongwei ^a   Marlatt, Michael W ^c,h   Castellani, Rudy J ^d   Nunomura, Akihiko ^e   Casadesus, Gemma ^f   Smith, Mark A ^a   Lee, Hyoung gon ^a   Perry, George ^a,g  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF YAMANASHI   (Japan)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g University of San Antonio   (United States)

^h Marie Curie Early Stage Training Program NEURAD Graduate School   (Germany)

Author keywords

Apolipoprotein E; Copper; Free radical; Iron; Lipid peroxidation; Oxygen species; Reactive; Vitamin E

Indexed keywords

AMYLOID BETA PROTEIN; ANTIOXIDANT; ASCORBIC ACID; DEFEROXAMINE; OMEGA 3 FATTY ACID;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL PROTECTION; CELL RESPIRATION; CHELATION; COGNITION; DIET SUPPLEMENTATION; DISEASE COURSE; GENE EXPRESSION; HUMAN; LIPID OXIDATION; LIPID PEROXIDATION; MITOCHONDRIAL MEMBRANE; MOLECULAR DYNAMICS; NEUROFIBRILLARY TANGLE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN AGGREGATION; RISK REDUCTION; TRANSGENE; VITAMIN INTAKE;

EID: 77957326921     PISSN: 15509702     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Cummings JL, Cole G. Alzheimer disease. Jama. 2002; 287(18):2335.
2. Alzheimer A. Uber einen eigenartigen schweren Krankheitsprozess der Hirnrinde. Zentralblatt fur Nervenkrankheiten. 1906; 25:1134.
3. Lee HG, et al. Amyloid beta: the alternate hypothesis. Curr Alzheimer Res. 2006; 3(1): 75.
4. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956; 11(3):298.
5. Harman D, Eddy DE, Noffsinger J. Free radical theory of aging: inhibition of amyloidosis in mice by antioxidants; possible mechanism. J Am Geriatr Soc. 1976; 24(5):203.
6. Smith MA, et al. Radical AGEing in Alzheimer's disease. Trends Neurosci. 1995; 18(4):172.
7. Perry G, et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med. 2002; 33(11):1475.
8. Perry G, et al. Reactive oxygen species mediate cellular damage in Alzheimer disease. J Alzheimers Dis. 1998; 1(1):45.
9. Pratico D, et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci. 2001; 21(12):4183.
10. Smith MA, et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A. 1997; 94(18):9866.
11. Reddy PH, Beal MF. Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev. 2005; 49(3):618.
12. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004; 430(7000):631.
13. Manczak M, et al. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet. 2006; 15(9):1437.
14. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med. 2008; 14(2):45.
15. Hirai K, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci. 2001; 21(9):3017.
16. Castellani R, et al. Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res. 2002; 70(3):357.
17. Sayre LM, et al. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem. 2000; 74(1):270.
18. Bondy SC, Guo-Ross SX, Truong AT. Promotion of transition metalinduced reactive oxygen species formation by beta-amyloid. Brain Res. 1998; 799(1):91.
19. Huang X, et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry. 1999; 38(24):7609.
20. Nunomura A, et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci. 1999; 19(6):1959.
21. Zhu X, et al. Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta. 2007; 1772(4):494.
22. Zhu X, et al. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 2004; 3(4):219.
23. Zhu X, et al. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech Ageing Dev. 2001; 123(1):39.
24. Bruce AJ, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med. 1996; 2(7):788.
25. Adams JD Jr, et al. Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E. Mol Chem Neuropathol. 1991; 14(3):213.
26. Jenner P. Oxidative damage in neurodegenerative disease. Lancet. 1994; 344(8925):796.
27. Lohr JB, Browning JA. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull. 1995; 31(1):159.
28. Sung S, et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. Faseb J. 2004; 18(2):323.
29. Morris MC, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA. 2002; 287(24):3230.
30. Morris MC, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003; 60(7):940.
31. Luchsinger JA, et al. Caloric intake and the risk of Alzheimer disease. Arch Neurol. 2002; 59(8):1258.
32. Hayashi T, et al. Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide. Free Radic Biol Med. 2007; 43(11):1552.
33. Nakamura M, et al. Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. Biochemistry. 2007; 46(44):12737.
34. Crapper McLachlan DR, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet. 1991; 337(8753):1304.
35. Castellani RJ, et al. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol (Berl). 2006; 111(6):503.